# Neil D. Gross

Source: https://onco.cc/people/neil-gross/  
OnCo record `neil-gross` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Houston surgeon who led the trial showing that giving cemiplimab before surgery can eliminate cutaneous squamous-cell carcinoma in about half of patients, sparing many from extensive operations.

## Summary

Neil Gross is a head and neck surgical oncologist at MD Anderson Cancer Center. He was first author of the 2022 New England Journal of Medicine report of a phase 2 trial of neoadjuvant cemiplimab in resectable stage II to IV cutaneous squamous-cell carcinoma, in which about half of patients had a pathological complete response at surgery, and leads studies of neoadjuvant immunotherapy in head and neck cancers.

## Fields

- Kind: Person
- Last checked: 2026-09-18
- Tags: skin; surgery; immunotherapy; trialist
- Role: Head and neck surgeon, MD Anderson Cancer Center
- Specialisms: Cutaneous squamous-cell carcinoma; Neoadjuvant immunotherapy; Head and neck surgery

## Connected records

- cancers: [Advanced cutaneous squamous cell carcinoma](https://onco.cc/cancers/advanced-cutaneous-scc/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/)
- institutions: [MD Anderson Cancer Center](https://onco.cc/institutions/md-anderson/)
- key papers: [Neoadjuvant cemiplimab for stage II to IV cutaneous squamous cell carcinoma](https://onco.cc/key-papers/paper-gross-neoadjuvant-cemiplimab-cscc-nejm-2022/)

---
JSON: https://onco.cc/api/v1/entities/neil-gross.json